KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Biocryst Pharmaceuticals (BCRX) Other Gross PP&E Adjustments (2016 - 2025)

Biocryst Pharmaceuticals filings provide 16 years of Other Gross PP&E Adjustments readings, the most recent being -$24.5 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 9.49% to -$24.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.5 million, a 9.49% decrease, with the full-year FY2025 number at -$24.5 million, down 9.49% from a year prior.
  • Other Gross PP&E Adjustments hit -$24.5 million in Q4 2025 for Biocryst Pharmaceuticals, down from -$7.7 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$4.2 million in Q4 2021 to a low of -$24.5 million in Q4 2025.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$7.9 million (2025), compared with a mean of -$10.2 million.
  • The widest YoY moves for Other Gross PP&E Adjustments: up 45.88% in 2023, down 187.67% in 2023.
  • Biocryst Pharmaceuticals' Other Gross PP&E Adjustments stood at -$4.2 million in 2021, then plummeted by 31.08% to -$5.4 million in 2022, then crashed by 187.67% to -$15.7 million in 2023, then plummeted by 43.04% to -$22.4 million in 2024, then fell by 9.49% to -$24.5 million in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$24.5 million (Q4 2025), -$7.7 million (Q3 2025), and -$7.9 million (Q2 2025) per Business Quant data.